Withdrawals due to adverse events · patients with tension‐type headache
It is very uncertain whether SSRIs or SNRIs changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · anemia in patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · patients with rheumatoid arthritis
Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in withdrawals due to Adverse events compared with placebo + MTX/DMARD (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis
Golimumab 50 mg every 4 weeks + MTX showed no clear difference in withdrawals due to Adverse Events compared with placebo + MTX (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
1 finding from 1 review
Adverse events for mother or child · For interventions, pregnant women and mothers of infants in the first year of life; for outcomes, children up to 6 years of age
1 finding from 1 review
Adverse event ‐ multiple pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes adverse events: multiple pregnancy compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Serenoa repens showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction
Serenoa repens in combination with other phytotherapy showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (low certainty).
1 finding from 1 review
Adverse events—all‐cause mortality · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Adverse events Assessed clinically · patients with functional dyspepsia
Curcuma longa showed no clear difference in adverse events Assessed clinically compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
STW5 (Iberogast) showed no clear difference in adverse events Assessed clinically compared with placebo (low certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
Peppermint/caraway oil showed no clear difference in adverse events Assessed clinically compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · lateral elbow pain
It is very uncertain whether autologous blood or PRP changes withdrawal due to adverse events  compared with placebo at 3 months' follow‐up (very low certainty).
1 finding from 1 review
Adverse events mild adverse events · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
1 finding from 1 review
Adverse events: death (all causes) · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
1 finding from 1 review
Adverse events ‐ pneumonia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: pneumonia 12‐month compared with placebo (low certainty).
1 finding from 1 review
Adverse events (nausea, dizziness) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
no estimate extracted
1 study · 3 participants
GRADE not reported